ADVANCED CONCEPT TECHNOLOGY DEMONSTRATIONS
COUNTERPROLIFERATION




MEDICAL BIOLOGICAL DEFENSE
OBJECTIVE:
  • DEVELOP, DEMONSTRATE, AND FIELD NEW VACCINES, DRUGS, AND DIAGNOSTICS KITS FOR PREVENTION, TREATMENT, AND DIAGNOSIS OF BIOLOGICAL WARFARE AGENTS. THIS DTO WILL PROTECT FORCES FROM THE CONSEQUENCES OF EXPOSURE TO BIOLOGICAL AGENTS AND FORCE SURVIVABILITY AND MISSION ACCOMPLISHMENT. THIS DTO WILL BE ACCOMPLISHED THROUGH THE DEVELOPMENT OF SEVERAL VACCINES, DRUGS, AND OTHER MEDICAL PRODUCTS TO DEFEND AGAINST ALL VALIDATED BIOLOGICAL WARFARE THREATS.

JUSTIFICATION:
  • PROVIDES CONTINUOUS PROTECTION AGAINST BIOLOGICAL WARFARE AGENTS.
  • SUPPORTS CINC/JROC COUNTERPROLIFERATION, JWCA PRIORITIES #6, #7, AND #8.
FIGURE IV-L-1
SCHEDULE AND FUNDING
    APPROACH:

  • DEVELOP NEW OR IMPROVED VACCINES TO PREVENT EFFECTS OF BIOLOGICAL WARFARE AGENTS.

  • DEVELOP NEW OR IMPROVED DRUGS AND MEDICAL TREATMENT TO COUNTER THE EFFECTS OF BIOLOGICAL WARFARE AGENTS FOLLOWING AGENT EXPOSURE.

  • DEVELOP NEW OR IMPROVED PORTABLE DIAGNOSTIC KITS FOR IMMEDIATE DIAGNOSIS OF CASUALTIES IN THE FIELD IN ORDER TO ALLOW EARLIEST APPLICATION OF MEDICAL TREATMENT.




MEDICAL BIOLOGICAL DEFENSE

OPERATIONAL CAPABILITY
CURRENT CAPABILITY
END DTO GOALS
ANTHRAX VACCINE
LIMITED
IMPROVED
BOTULINUM TOXOID
STRAINS A-E
ALL AGENT STRAINS
PLAGUE VACCINE
YES (NO PROTECTION AGAINST INHALATION HAZARD)
YES (NO PROTECTION AGAINST INHALATION HAZARD)
SEB TOXIN VACCINE
NO
YES
VEE/WEE/EEE VACCINE
NO
YES
FIELD DEPLOYABLE DIAGNOSTIC KIT
NO
YES




MEDICAL CHEMICAL DEFENSE
    OBJECTIVE:
  • DEVELOP, DEMONSTRATE, AND FIELD NEW PROPHYLACTIC MEASURES, DRUGS, AND DIAGNOSTIC KITS FOR PREVENTION, TREATMENT, AND DIAGNOSIS OF CHEMICAL WARFARE AGENTS. THIS DTO WILL PROTECT FORCES FROM THE CONSEQUENCES OF EXPOSURE TO CHEMICAL AGENTS AND FORCE SURVIVABILITY AND MISSION ACCOMPLISHMENT. THIS DTO WILL BE ACCOMPLISHED THROUGH THE DEVELOPMENT OF SEVERAL DRUGS AND OTHER MEDICAL PRODUCTS TO DEFEND AGAINST ALL CHEMICAL WARFARE THREATS.

    JUSTIFICATION:
  • PROVIDE CONTINUOUS PROTECTION AGAINST CHEMICAL WARFARE AGENTS.
  • SUPPORTS CINC/JROC COUNTERPROLIFERATION, JWCA PRIORITIES #6, AND #7.
FIGURE IV-L-2
SCHEDULE AND FUNDING
    APPROACH:

  • DEVELOP VESICANT AGENT COUNTERMEASURES.

  • DEVELOP REACTIVE/CATALYTIC NERVE AGENT PROPHYLAXES.

  • DEVELOP REACTIVE TOPICAL SKIN PROTECTANT.




MEDICAL CHEMICAL DEFENSE

OPERATIONAL CAPABILITY
CURRENT CAPABILITY
END DTO GOALS
VESICANT AGENT COUNTERMEASURES
NO
YES
REACTIVE/CATALYTIC NERVE AGENT PROPHYLAXES
NO
YES
REACTIVE TOPICAL SKIN PROTECTANT
NO
YES



COUNTERPROLIFERATION - COUNTERFORCE - ACTD
PHASES I AND II
OBJECTIVE:
PHASE I - USE CURRENT/NEAR TERM TECHNOLOGIES TO DEMONSTRATE CAPABILITIES AGAINST SOFT, ABOVE-GROUND BIOLOGICAL WEAPON STORAGE FACILITY.

PHASE II - USE CURRENT/EMERGING TECHNOLOGIES TO DEMONSTRATE SUBSTANTIALLY IMPROVED CAPABILITIES AGAINST SIMULATED HARDENED, CHEMICAL WEAPON PRODUCTION FACILITIES.


JUSTIFICATION:
THESE TARGETS HAVE BEEN IDENTIFIED AS PRIORITY TARGETS BY CINCs. 		FIGURE IV-L-3
SCHEDULE AND FUNDING
    APPROACH:

  • USE INTELLIGENCE DATA TO CONSTRUCT REALISTIC FACILITIES AS MODELS FOR PHASE II DEMONSTRATION.

  • COORDINATE WITH USEUCOM ON WEAPON AND ATTACK SCENARIO FOR DEMONSTRATION.

  • USE POST-ATTACK DAMAGE ASSESSMENT TO EVALUATE TARGET PLANNING AND COLATERAL EFFECTS MODELS THAT ARE TO BE PROVIDED TO CINCEUR.

  • PROVIDE RESIDUAL CAPABILITY IN TERMS OF COUNTERFORCE TACTICS, MISSION EFFECTIVENESS MODELS, AND COLLATERAL EFFECTS PREDICTIONS.



COUNTERPROLIFERATION - COUNTERFORCE - ACTD EXIT CRITERIA
PHASES I AND II



THIS ACTD DEVELOPS CALCULATIONAL TOOLS, WEAPON EMPLOYMENT TACTICS, DAMAGE ASSESSMENT, AND COLATERAL EFFECTS TOOLS AND INTEGRATES THEM TO PROVIDE THE WARFIGHTER A RAPID, LETHAL TARGETING METHODOLOGY WITH MINIMAL COLLATERAL EFFECTS. THIS REQUIRES THAT THE ACTD PHASES I AND II:

  • DEMONSTRATE AN OPERATIONAL APPLICATION AGAINST A REASONABLE SILMULATED TARGET (ABOVE GROUND BIOLOGICAL WMD STORAGE FACILITY FOR PHASE I AND A HARDENED CUT-AND-COVER CHEMICAL WMD PRODUCTION FACILITY FOR PHASE II).

  • DEMONSTRATE A CAPABILITY TO DETECT AND CHARACTERIZE TARGET FACILITIES, A TARGETING METHODOLOGY TO KILL OR DENY ACCESS, AND AN ABILITY TO REDUCE COLLATERAL DAMAGE RELATIVE TO CURRENT TARGETING TACTICS.



COUNTERPROLIFERATION - COUNTERFORCE - ACTD
PHASES III-V
OBJECTIVE:
DEVELOP METHODOLOGIES, INTEGRATE, DEMONSTRATE, AND TRANSITION TO USERS A CAPABILITY TO DEFEAT OR DENY USE OF BIOLOGICAL, CHEMICAL, AND NUCLEAR WMD-RELATED FACILITIES INCLUDING C3I LOACTED ON THE SURFACE, SHALLOW BURIED, OR DEEPLY BURRIED TUNNELS.

JUSTIFICATION:
THESE WMD FACILITIES ARE THOSE THAT HAVE NOT BEEN ADDRESSED IN THE PHASES I AND II PROGRAMS. THEY HAVE UNIQUE TARGETING CONCERNS REQUIRING NEW WEAPON/WARHEAD CAPABILITIES TO ADDRESS DEFEAT WHILE MINIMIZING COLLATERAL EFFECTS. 		FIGURE IV-L-4
SCHEDULE AND FUNDING
    APPROACH:

  • USE INTELLIGENCE DATA TO CONSTRUCT REALISTIC FACILITIES AS MODELS FOR PHASE II DEMONSTRATION.

  • COORDINATE WITH USEUCOM ON WEAPON AND ATTACK SCENARIO FOR DEMONSTRATION.

  • USE POST-ATTACK DAMAGE ASSESSMENT TO EVALUATE TARGET PLANNING AND COLATERAL EFFECTS MODELS THAT ARE TO BE PROVIDED TO CINCEUR.

  • PROVIDE RESIDUAL CAPABILITY IN TERMS OF COUNTERFORCE TACTICS, MISSION EFFECTIVENESS MODELS, AND COLLATERAL EFFECTS PREDICTIONS.



COUNTERPROLIFERATION - COUNTERFORCE - ACTD EXIT CRITERIA
PHASES III-V



THESE PHASES OF THE ACTD MUST DEMONSTRATE A CAPABILITY TO IDENTIFY, CHARACTERIZE, TARGET, AND KILL OR DENY USE OF BIOLOGICAL, CHEMICAL, AND NUCLEAR WMD-RELATED FACILITIES WHILE MINIMIZING COLLATERAL EFFECTS RESULTING FROM DAMAGE TO TARGET FACILITIES.

  • A SUCCESSFUL DEMONSTRATION MUST BE EXECUTED AGAINST REPRESENTATIVE TARGET SETS: SURFACE TRANSPORTER ERECTOR LAUNCHERS (TELs), TELs IN TUNNEL, AND BIOLOGICAL WMD PRODUCTION AND LOAD & FILL FACILITIES, NUCLEAR WMD PRODUCTION FACILITIES, NUCLEAR WMD C3I FACILITIES, AND DEEPLY BURIED (E.G., TUNNEL EMPLACED) FACILITIES.

  • THE PRODUCTS OF THIS EFFORT WILL BE DEMONSTRATED WEAPON AND SENSOR SYSTEMS AS WELL AS TARGET PLANNING TOOLS, AND BDA TOOLS UPDATED AND EXPANDED TO ADDRESS EACH OF THE TARGET AND WEAPON SYSTEMS EMPLOYED FOR THIS TARGET SET.

  • RESIDUAL ITEMS TO BE SUPPORTED FOR TWO YEARS AFTER THE DEMONSTRATION INCLUDE: HARDWARE, TOOLS, AND SENSORS.